Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Jin Medical International's selling, general, & admin. expense for the
six
months ended in Mar. 2026 was $2.16 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $3.84 Mil.
Jin Medical International (NAS:ZJYL) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Jin Medical International Selling, General, & Admin. Expense Related Terms
Jin Medical International Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Jin Medical International's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International Selling, General, & Admin. Expense Chart
ZJYL vs RGNT, BNGO, RVP: Selling, General, & Admin. Expense Comparison
For the Medical Instruments & Supplies subindustry, Jin Medical International's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Jin Medical International's Selling, General, & Admin. Expense falls into.
Jin Medical International Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $3.84 Mil mean?
Jin Medical International (ZJYL) has a Selling, General, & Admin. Expense of $3.84 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Jin Medical International and its competitors.
Is Jin Medical International's Selling, General, & Admin. Expense too high?
Jin Medical International's current Selling, General, & Admin. Expense is $3.84 Mil. Overall, Jin Medical International has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's Selling, General, & Admin. Expense compare to RGNT and BNGO?
Jin Medical International's Selling, General, & Admin. Expense of $3.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Jin Medical International and its competitors. Jin Medical International's current Selling, General, & Admin. Expense is $3.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.84, compared to a current price of $3.36 — trading 73.8% below its estimated fair value. The current Selling, General, & Admin. Expense is $3.84 Mil. Jin Medical International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current Selling, General, & Admin. Expense is $3.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $3.36 is trading 73.8% below its estimated GF Value™ of $12.84.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
Selling, General, & Admin. Expense: $3.84 Mil
GF Value™: $12.84 vs. price of $3.36 (73.8% below fair value)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
66GF Score
Get the complete analysis for ZJYL
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
